## Overview of Heparin-Induced Thrombocytopenia (HIT) Heparin-induced thrombocytopenia (HIT) is a life-threatening, immune-mediated adverse drug reaction caused by the formation of antibodies against complexes of platelet factor 4 (PF4) and heparin. Unlike most other forms of drug-induced thrombocytopenia, HIT is paradoxical in that it is significantly associated with an increased risk of venous and arterial thrombosis rather than bleeding. It represents a prothrombotic state where the platelet count typically drops by more than 50% from the baseline, even if the absolute count remains within or near the normal range. ### Pathophysiology The central mechanism involves the binding of heparin (especially unfractionated heparin) to Platelet Factor 4 (PF4), a positively charged protein released from alpha-granules of activated platelets. This binding creates a neoantigen. In susceptible individuals, B-cells produce IgG antibodies against the PF4-heparin complex. These IgG-PF4-heparin immune complexes then bind to the FcyRIIa receptors on the surface of platelets, leading to massive platelet activation, the release of more PF4, and the generation of procoagulant microparticles. This cycle creates a hypercoagulable state. Additionally, these complexes activate endothelial cells and monocytes, further promoting thrombin generation. ### Clinical Presentation and Timing HIT is classified into two types, though D75.82 refers specifically to the immune-mediated Type II HIT. Type I HIT is a non-immune, mild, transient drop in platelets occurring within the first two days of heparin exposure. Type II HIT typically manifests 5 to 14 days after the initiation of heparin therapy. However, 'rapid-onset HIT' can occur within 24 hours if the patient has been exposed to heparin in the previous 30 to 100 days and still possesses circulating antibodies. Conversely, 'delayed-onset HIT' can manifest several days after heparin has been discontinued. ### Diagnosis and Risk Stratification Clinicians utilize the '4Ts Score' to determine the pre-test probability of HIT. This scoring system evaluates: (1) Thrombocytopenia (degree of platelet drop), (2) Timing of the platelet drop, (3) Thrombosis or other sequelae, and (4) oTher causes of thrombocytopenia. A low score (0-3) has a high negative predictive value, effectively ruling out HIT. Moderate to high scores necessitate laboratory testing. Diagnostic labs include highly sensitive Platelet Factor 4 (PF4) immunoassays (ELISA) and highly specific functional assays, such as the Serotonin Release Assay (SRA) or Heparin-Induced Platelet Aggregation (HIPA) test. ### Management and Therapeutic Principles The standard of care involves the immediate cessation of all heparin products (including flushes and heparin-coated catheters). Because of the high risk of thrombosis (approximately 5-10% daily in the first few days), alternative non-heparin anticoagulation must be initiated immediately. Common choices include direct thrombin inhibitors like argatroban or bivalirudin, or the factor Xa inhibitor fondaparinux. Warfarin is strictly contraindicated during the acute phase of HIT because it can precipitate venous limb gangrene and skin necrosis by depleting Protein C while the prothrombotic state remains active. Warfarin should only be introduced once the platelet count has recovered to at least 150,000/µL and overlapped with a non-heparin anticoagulant for at least 5 days.
Distinguish between HIT Type I and Type II (D75.82 is specific for Type II)
Example: Patient diagnosed with Heparin-induced thrombocytopenia (HIT) Type II following 6 days of UFH therapy for DVT. Platelet count dropped from 250k to 85k (66% decrease). 4Ts score: 7 (High probability). Documentation supports D75.82, noting this is an immune-mediated drug reaction and not the benign non-immune Type I variant.
Billing Focus: Identify the type of HIT; D75.82 should only be used for the immune-mediated Type II HIT, which is the clinically significant variety.
Document the '4Ts' score to support clinical validity and medical necessity for testing
Example: Evaluated patient for suspected HIT; 4Ts score calculated as 6 (Thrombocytopenia: 2; Timing: 2; Thrombosis: 1; Other causes: 1). Heparin PF4 IgG ELISA ordered. Heparin therapy discontinued immediately; Argatroban started at 2 mcg/kg/min. Documentation of clinical scoring supports the transition to high-cost alternative anticoagulants.
Billing Focus: Specificity in clinical indicators (4Ts score) justifies the necessity of high-complexity MDM and expensive lab assays like SRA.
Explicitly state the presence of thrombosis (HITT) if applicable
Example: Patient with HIT Type II (D75.82) complicated by new acute proximal DVT of the left common femoral vein (I82.412), also known as Heparin-induced thrombocytopenia with thrombosis (HITT). Risk of arterial gangrene is noted. Management involves transition to direct thrombin inhibitor.
Billing Focus: Laterality of thrombosis (left common femoral vein) and the causal link to HIT must be explicitly documented to code both HIT and the specific thrombotic site.
Specify the causative Heparin agent (UFH vs. LMWH)
Example: Patient developed HIT Type II (D75.82) after 8 days of Enoxaparin (LMWH) 40mg daily for post-op prophylaxis. Patient has no history of heparin exposure in the last 90 days. Adverse effect of anticoagulant is coded (T45.515A).
Billing Focus: Documentation should allow for the secondary coding of T45.515A (Adverse effect of antithrombotic drugs) to provide a complete clinical picture.
Detail the transition plan for oral anticoagulation (Warfarin contraindication)
Example: HIT Type II (D75.82) confirmed. Warfarin is contraindicated until platelets recover to >150k due to the risk of venous limb gangrene. Currently bridging with Bivalirudin. Platelets monitored daily. This documentation explains the prolonged hospital stay and intensive monitoring requirement.
Billing Focus: Detailed management plans justify higher levels of E/M coding (99215 or 99233) due to the high risk of treatment complications.
Used for monitoring patients recovering from HIT or managing long-term non-heparin anticoagulation after a HIT event.
Required when a HIT patient has complex comorbid thrombotic events (HITT) or multi-system complications requiring extensive coordination.
Often used as a technical component of detecting Heparin-PF4 complexes.
The gold standard confirmatory test for HIT that measures platelet activation in the presence of heparin.
The primary monitoring tool for tracking the 50% drop and subsequent recovery of platelets in HIT.
Required to screen for subclinical DVT in any patient newly diagnosed with HIT.
Initial consultation for a complex patient with acute thrombocytopenia and suspected HIT with high risk of thrombosis.
Used in severe HITT cases where arterial 'white clots' cause limb ischemia.
Standard billing for inpatient management of acute HIT where life-threatening thrombosis is present.
Used to rule out other causes of immune thrombocytopenia/hemolysis.